Background: In patients with triple-negative breast cancer (TNBC), the extent of tumor-infiltrating lymphocytes (TILs) in the residual disease after neoadjuvant chemotherapy (NACT) is associated with better prognosis. Our objective was to develop a gene signature frompretreatment samples to predict the extent of TILs after NACT and then to test its prognostic value on survival. Patients and methods: Using 99 pretreatment samples, we generated a four-gene signature associated with high post-NACT TILs. Prognostic value of the signature on distant relapse-free survival (DRFS) was first assessed on the training set (n=99) and then on an independent validation set (n=115). Results: A four-gene signature combining the expression levels of HLF, CXCL13, SULT1E1, and GBP1 was developed in baseline samples to predict the extent of lymphocytic infiltration after NACT. In a multivariate analysis performed on the training set, this signature was associated with DRFS [hazard ratio (HR): 0.28, for a one-unit increase in the value of the four-gene signature, 95% confidence interval (CI): 0.13-0.63)]. In a multivariate analysis performed on an independent validation set, the four-gene signature was significantly associated with DRFS (HR: 0.17, 95% CI: 0.06-0.43). The four-gene signature added significant prognostic information when compared with the clinicopathologic pretreatment model (likelihood ratio test in the training set P=0.004 and in the validation set P=0.002). Conclusions: A four-gene signature predicts high levels of TILs after anthracycline-containing NACT and outcome in patients with TNBC and adds prognostic information to a clinicopathological model at diagnosis.
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer / C. Criscitiello, M.A. Bayar, G. Curigliano, F.W. Symmans, C. Desmedt, H. Bonnefoi, B. Sinn, G. Pruneri, C. Vicier, J.Y. Pierga, C. Denkert, S. Loibl, C. Sotiriou, S. Michiels, F. André. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 29:1(2018), pp. mdx691.162-mdx691.169.
Titolo: | A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer |
Autori: | |
Parole Chiave: | Breast cancer; Gene signature; Neoadjuvant therapy; Residual disease; Tumor-infiltrating lymphocytes; Hematology; Oncology |
Settore Scientifico Disciplinare: | Settore MED/06 - Oncologia Medica |
Data di pubblicazione: | 2018 |
Rivista: | |
URL: | http://annonc.oxfordjournals.org/ |
Tipologia: | Article (author) |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1093/annonc/mdx691 |
Appare nelle tipologie: | 01 - Articolo su periodico |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
mdx691.pdf | Publisher's version/PDF | Administrator Richiedi una copia |